Landscape of reversion alterations in homologous recombination genes reveals evolutionary constraints
Decker, B.; Sisoudiya, S. D.; Thornton, J.; Cui, C.; Harada, T.; Solieva, S. O.; Madison, R. W.; Datta, A.; Shi, T.; Guintini, F.; Fleischmann, Z.; Hartman, M.; Bailey, S. T.; Leibowitz, J. A.; Sokol, E. S.; Schrock, A. B.; Frampton, G. M.; Couch, F. J.; Reiss, K. A.; Domchek, S. M.; Bowman, G. R.; Greenberg, R. A.; Sivakumar, S.; Nathanson, K. L.
Show abstract
Reversion mutations (REVs) restore homologous recombination repair (HRR) and confer resistance to PARP inhibitors (PARPi) in HR-deficient cancers. Yet, their prevalence, mechanisms, and biological constraints remain undefined. We analyzed genomic profiling of 609,464 tissue and liquid biopsy samples across multiple cancer types to delineate the pan-cancer landscape of REVs. REVs were identified in eight HRR genes, most frequently BRCA2 and BRCA1 and notably never in ATM or CHEK2. REVs exclusively impacted truncating pathogenic variants, predominantly through large in-frame and exon-level deletions, associated with repetitive sequences. Conserved functional domains are relatively depleted of REVs. Structural modeling and functional studies support that exon-level deletions preserve critical domain architecture and confer PARPi resistance. The study establishes HRR reversion as a structurally permissive, yet evolutionarily constrained, resistance mechanism with implications on response, monitoring, and therapeutic strategy. One Sentence SummaryHomologous recombination reversion evolves through structurally tolerated, microhomology-driven alterations that restore DNA repair under therapeutic selection across cancers.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 Fusions 96%
- EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition 95%
- The DiffInvex evolutionary model for conditional somatic selection identifies chemotherapy resistance genes in 10,000 cancer genomes 95%
Similar papers in this journal
- Aneuploidy and deregulated DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers 95%
- Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance 95%
- Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving calcium-calcineurin-NFAT signaling 94%
Similar papers in this journal
- Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns 97%
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 95%
- NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.